16269-06-0

Basic information

• Product Name: 9-PHENYL-NONANOIC ACID
• Synonyms: 9-PHENYL-NONANOIC ACID;9-Phenyl nonansyre;9-Phenylnonanoic acid 98%;Benzenenonanoic acid
• CAS NO: 16269-06-0
• Molecular Formula: C₁₅H₂₂O₂
• Molecular Weight: 234.33
• Mol File: 16269-06-0.mol

Chemical Properties

• Melting Point: 39-40 °C
• Boiling Point: 383.4 °C at 760 mmHg
• Flash Point: 280.2 °C
• Appearance: /
• Density: 1.008 g/cm³
• Vapor Pressure: 1.46E-06mmHg at 25°C
• Refractive Index: 1.512
• PKA: 4.78±0.10(Predicted)
• CAS DataBase Reference: 9-PHENYL-NONANOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 9-PHENYL-NONANOIC ACID(16269-06-0)
• EPA Substance Registry System: 9-PHENYL-NONANOIC ACID(16269-06-0)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 16269-06-0(Hazardous Substances Data)

Usage

Uses

Used in Food Industry:
9-PHENYL-NONANOIC ACID is used as a natural additive for enhancing the flavor and aroma of various food products. Its presence in butter fat contributes to the unique taste and smell of this widely consumed dairy product.
Used in Biodegradable Plastics Production:
9-PHENYL-NONANOIC ACID serves as a crucial precursor in the biosynthesis of medium-chain-length poly-hydroxyalkanoates (mcl-PHAs) in Pseudomonas putida U. These mcl-PHAs are biodegradable plastics that have potential applications in various industries, including packaging, agriculture, and medical devices, as they offer an environmentally friendly alternative to traditional petroleum-based plastics.
Used in Chemical Synthesis:
Due to its unique chemical structure, 9-PHENYL-NONANOIC ACID can be used as a building block in the synthesis of various chemicals, including pharmaceuticals, fragrances, and other specialty chemicals. Its versatility in chemical reactions makes it a valuable compound for the development of new products and materials.

InChI:InChI=1/C15H22O2/c16-15(17)13-9-4-2-1-3-6-10-14-11-7-5-8-12-14/h5,7-8,11-12H,1-4,6,9-10,13H2,(H,16,17)

Upstream product

• 859491-10-4 5-(4-phenyl-butyl)-thiophene-2-carboxylic acid 
• 24197-55-5 9-phenylnonanoic acid methyl ester 
• 148112-00-9 2-(4-phenylbutyl)thiophene 
• 874525-54-9 1-(2-thienyl)-4-phenylbutan-1-one 
• 854006-60-3 4-(5-benzyl-[2]thienyl)-4-oxo-butyric acid 
• 3208-26-2 9-phenyl-1-hydroxynonane 
• 104-53-0 3-phenyl-propionaldehyde 
• 928753-93-9 (5-carboxypentyl)triphenylphosphonium bromide 
• 41059-02-3 9-bromononanoic acid 
• 50530-09-1 9-bromononanoic acid sodium salt 
• 100-58-3 phenylmagnesium bromide 
• 207132-52-3 9-phenylnon-8-enoic acid 
• 645-45-4 hydrocinnamic acid chloride 
• 16275-33-5 2-(3-phenylpropanoyl)cyclohexanone 

Downstream Products

• 4352-53-8 9-cyclohexyl-nonanoic acid 
• 1002100-54-0 C₂₅H₃₂N₂O₂ 
• 1033694-62-0 C₁₅H₂₁N₃O 
• 1453071-44-7 3-(N-hydroxy-9-phenylnonanamido)propanoic acid 
• 1454255-89-0 C₂₂H₃₅NO₄ 
• 1454255-83-4 C₂₉H₄₁NO₄ 
• 1133869-78-9 N-9-phenylnonanoyl-L-homoserine lactone 
• 103602-67-1 9-phenyl-1-bromononane 
• 61875-57-8 9-phenylnonanoyl chloride 
• 3208-26-2 9-phenyl-1-hydroxynonane 

Relevant articles and documents

DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC)

This present disclosure relates to protein kinase C (PKC) modulating compounds, methods of treating a subject with cancer using the compounds, and combination treatments with a second therapeutic agent.

A Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA1), UCM-05194, Shows Efficacy in Neuropathic Pain Amelioration

Neuropathic pain (NP) is a complex chronic pain state with a prevalence of almost 10% in the general population. Pharmacological options for NP are limited and weakly effective, so there is a need to develop more efficacious NP attenuating drugs. Activation of the type 1 lysophosphatidic acid (LPA1) receptor is a crucial factor in the initiation of NP. Hence, it is conceivable that a functional antagonism strategy could lead to NP mitigation. Here we describe a new series of LPA1 agonists among which derivative (S)-17 (UCM-05194) stands out as the most potent and selective LPA1 receptor agonist described so far (Emax = 118%, EC50 = 0.24 μM, KD = 19.6 nM; inactive at autotaxin and LPA2-6 receptors). This compound induces characteristic LPA1-mediated cellular effects and prompts the internalization of the receptor leading to its functional inactivation in primary sensory neurons and to an efficacious attenuation of the pain perception in an in vivo model of NP.

New hydroxamic acid derivative and use thereof

PROBLEM TO BE SOLVED: To provide a novel hydroxamic acid derivative having an inhibitory activity against KDM7 being a histone demethylase, and a cancer cell proliferation-suppressing action, and to provide medicines (particularly a KDM7 inhibitor and anticancer agent) using the derivative.SOLUTION: A compound represented by general formula (I) (wherein R is a linear, branched or annular alkyl group; and n is an integer of ≥6), a salt thereof, hydrate, solvate or prodrug are provided. The compound can be used as a medicine (particularly an anticancer agent) or a KDM7 inhibitor.

Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity

Histone Nε-methyl lysine demethylases KDM2/7 have been identified as potential targets for cancer therapies. On the basis of the crystal structure of KDM7B, we designed and prepared a series of hydroxamate analogues bearing an alkyl chain. Enzyme assays revealed that compound 9 potently inhibits KDM2A, KDM7A, and KDM7B, with IC50s of 6.8, 0.2, and 1.2 μM, respectively. While inhibitors of KDM4s did not show any effect on cancer cells tested, the KDM2/7-subfamily inhibitor 9 exerted antiproliferative activity, indicating the potential for KDM2/7 inhibitors as anticancer agents.

Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: Modulation at the N-portion of biphenyl-3-yl alkylcarbamates

Alkylcarbamic acid biphenyl-3-yl esters are a class of fatty acid amide hydrolase (FAAH) inhibitors that comprises cyclohexylcarbamic acid 3′-carbamoylbiphenyl-3-yl ester (URB597), a compound with analgesic, anxiolytic-like and antidepressant-like propert

New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain

N-Arachidonoylserotonin (AA-5-HT, 1a) is an inhibitor of fatty acid amide hydrolase (FAAH) that acts also as an antagonist of transient receptor potential vanilloid-type 1 (TRPV1) channels and is analgesic in rodents. We modified the chemical structure of 1a with the aim of developing "hybrid" FAAH/TRPV1 blockers more potent than the parent compound or obtaining analogues with single activity at either of the two targets to study the mechanism of the analgesic action of 1a. Thirty-eight AA-5-HT analogues, containing a serotonin "head" bound to a variety of lipophilic moieties via amide, urea, or carbamate functionalities, were synthesized. Unlike 1a, most of the new compounds possessed activity at only one of the two considered targets. The amides 1b and 1c of α- and γ-linolenic acid, however, showed "hybrid" activity similar to 1a. The carbamate 3f (OMDM106), although unable to antagonize TRPV1 receptors, was the most potent FAAH inhibitor in this study (IC50 = 0.5 μM). Compounds 3f and 1m (OMDM129), which exhibited activity at only FAAH or TRPV1, respectively, were 10-fold less potent than 1a at preventing formalin-induced hyperalgesia in mice.

Development of an enzyme-linked immunosorbent assay for the determination of the linear alkylbenzene sulfonates and long-chain sulfophenyl carboxylates using antibodies generated by pseudoheterologous immunization

ELISA methods have been developed for screening contamination of water resources by linear alkyl benzene sulfonates (LAS) or the most immediate degradation products, the long chain sulfophenyl carboxylates, SPCs. The assay uses antibodies raised through pseudoheterologous immunization strategies using an equimolar mixture of two immunogens (SFA-KLH and 13C13-SPC-KLH) prepared by coupling N-(4-alkylpnenyl)sulfonyl-3-aminopropanoic acid (SFA) andp-(1-carboxy-13-tridecyl)-phenylsulfonic acid (13C13-SPC) to keyhole limpet hemocyanin (KLH). The immunizing haptens have been designed to address recognition versus two different epitopes of the molecule. The SFA hapten maximizes recognition of the alkyl moiety while preserving the complexity of the different alkyl chains present in the LAS technical mixture. The 13C13-SPC hapten addresses recognition of the common and highly antigenic phenylsulfonic group. The antisera raised using this strategy have been shown to be superior to those obtained through homologous immunization procedures using a single substance. By using an indirect ELISA format, LAS and long-chain SPCs can be detected down to 1.8 and 0.2 μg L-1, respectively. Coefficients of variation of 6 and 12% within and between assays, respectively, demonstrate immunoassay reproducibility. The assay can be used in media with a wide range of pH and ionic strength values. Preliminary experiments performed to assess matrix effects have demonstrated the potential applicability of the method as a screening tool to assess contamination by these types of surfactants in natural water samples.

Synthesis and Identification of ω-Phenylalkylcatechols in Burmese Lac

The presence of 3-(10'-phenyldecyl)- (2) (2percent), 3-(12'-phenyldodecyl)- (3) (6percent), 4-(10'-phenyldecyl)- (4) (0.3percent) and 4-(12'-phenyldodecyl)-benzene-1,2-diol (5) (0.3percent) in Burmese lac, the sap of Melanorrhoea usitata Wall has been confirmed by the synthesis of these compounds and a comparison of the gas chromatographic retention times and the mass spectral characteristic of their bis-O-(trimethylsilyl) derivatives with the derivatives of the natural products.Typically, 3,4-bis(benzyloxy)benzaldehyde (7) on Wittig reaction with triphenyl(11-phenylundecyl)phosphonium bromide (20) and subsequent catalytic hydrogenation of the resultant olefin gave compound (5) in 59percent overall yield.